SG11201806214RA - Clinical assessment of m-protein response in multiple myeloma - Google Patents
Clinical assessment of m-protein response in multiple myelomaInfo
- Publication number
- SG11201806214RA SG11201806214RA SG11201806214RA SG11201806214RA SG11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA SG 11201806214R A SG11201806214R A SG 11201806214RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- clinical assessment
- mor202
- planegg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158714 | 2016-03-04 | ||
| PCT/EP2017/055011 WO2017149122A1 (en) | 2016-03-04 | 2017-03-03 | Clinical assessment of m-protein response in multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806214RA true SG11201806214RA (en) | 2018-08-30 |
Family
ID=55745535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806214RA SG11201806214RA (en) | 2016-03-04 | 2017-03-03 | Clinical assessment of m-protein response in multiple myeloma |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11618789B2 (https=) |
| EP (1) | EP3423498A1 (https=) |
| JP (4) | JP7362250B2 (https=) |
| KR (1) | KR102427948B1 (https=) |
| CN (1) | CN108699161B (https=) |
| AU (2) | AU2017226960B2 (https=) |
| IL (2) | IL260750B2 (https=) |
| SG (1) | SG11201806214RA (https=) |
| WO (1) | WO2017149122A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019209730A1 (en) | 2018-04-24 | 2019-10-31 | Helena Laboratories Corporation | Removal of interfering factors from serum protein electrophoresis profiles |
| AU2019338999A1 (en) | 2018-09-11 | 2021-03-18 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD38 antibody, antigen-binding fragment thereof, and pharmaceutical use |
| JP7687956B2 (ja) | 2019-03-15 | 2025-06-03 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物 |
| WO2023094696A1 (en) * | 2021-11-29 | 2023-06-01 | Morphosys Ag | Methods for reducing anti-cd38 mab drug interference in serological assays |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3912610A (en) * | 1974-07-23 | 1975-10-14 | Icl Scient | Method for electroquantitative determination of proteins |
| US4102990A (en) * | 1977-12-05 | 1978-07-25 | General Electric Company | Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling |
| US4661586A (en) | 1981-11-17 | 1987-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Monoclonal anti-idiotype antibodies |
| US4578350A (en) * | 1983-09-23 | 1986-03-25 | Syntex (U.S.A.) Inc. | Immunoassays employing protected labels |
| US6936464B1 (en) * | 1992-10-02 | 2005-08-30 | Cancer Research Technology Limited | Immune responses to fusion proteins |
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| WO1999062526A2 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| US7348139B1 (en) * | 2001-04-13 | 2008-03-25 | The Johns Hopkins University School Of Medicine | SOCS-1 gene methylation in cancer |
| US6902669B2 (en) | 2002-09-13 | 2005-06-07 | Fleetguard, Inc. | Filter cartridge with floating seal |
| EP1544215A1 (en) | 2003-12-17 | 2005-06-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Human anti-idiotypic antibody fragments that mimic HER-2/neu |
| KR20140066259A (ko) | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| AU2005235811B2 (en) * | 2004-02-06 | 2011-11-03 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
| HUE025945T2 (en) | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| JP5225069B2 (ja) | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| CA2625681C (en) | 2005-10-12 | 2016-08-02 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 |
| WO2007146038A2 (en) * | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US8969024B2 (en) * | 2007-08-28 | 2015-03-03 | Abbvie Biotechnology Ltd | Compositions and methods comprising binding proteins for adalimumab |
| US20110151494A1 (en) * | 2008-06-30 | 2011-06-23 | H. Lee Moffit Cancer & Research Institute | Methods and materials for monitoring myeloma using quantitative mass spectrometry |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| DK2621531T3 (en) | 2010-09-27 | 2017-02-27 | Morphosys Ag | ANTI-CD38 ANTIBODY AND LENALIDOMIDE OR BORTEZOMIB FOR TREATMENT OF MULTIPLE MYELOM AND NHL |
| JP2014504850A (ja) | 2010-09-30 | 2014-02-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| PL2831237T3 (pl) | 2012-03-30 | 2018-06-29 | The Board Of Regents Of The University Of Oklahoma | Polimery heparosanu o wysokiej masie cząsteczkowej i sposoby ich wytwarzania i zastosowania |
| MX368288B (es) | 2012-09-25 | 2019-09-27 | Morphosys Ag | Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple. |
| BR112015027313A2 (pt) | 2013-04-29 | 2017-09-26 | Teva Pharmaceuticals Australia Pty Ltd | anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado |
| US20150118251A1 (en) | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
-
2017
- 2017-03-03 WO PCT/EP2017/055011 patent/WO2017149122A1/en not_active Ceased
- 2017-03-03 KR KR1020187026496A patent/KR102427948B1/ko active Active
- 2017-03-03 CN CN201780014944.6A patent/CN108699161B/zh active Active
- 2017-03-03 EP EP17708766.5A patent/EP3423498A1/en active Pending
- 2017-03-03 AU AU2017226960A patent/AU2017226960B2/en active Active
- 2017-03-03 SG SG11201806214RA patent/SG11201806214RA/en unknown
- 2017-03-03 JP JP2018545438A patent/JP7362250B2/ja active Active
- 2017-03-03 IL IL260750A patent/IL260750B2/en unknown
- 2017-03-03 US US16/080,870 patent/US11618789B2/en active Active
- 2017-03-03 IL IL305540A patent/IL305540B2/en unknown
-
2022
- 2022-02-03 JP JP2022015613A patent/JP7331168B2/ja active Active
-
2023
- 2023-02-14 US US18/168,930 patent/US20230203189A1/en not_active Abandoned
- 2023-08-08 JP JP2023129240A patent/JP7557023B2/ja active Active
-
2024
- 2024-03-07 AU AU2024201503A patent/AU2024201503A1/en active Pending
- 2024-08-13 US US18/802,877 patent/US20240392034A1/en active Pending
- 2024-09-11 JP JP2024157490A patent/JP7835815B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL260750B1 (en) | 2023-10-01 |
| IL260750A (https=) | 2018-09-20 |
| CN108699161A (zh) | 2018-10-23 |
| JP2023157927A (ja) | 2023-10-26 |
| WO2017149122A1 (en) | 2017-09-08 |
| KR20180118151A (ko) | 2018-10-30 |
| CA3016098A1 (en) | 2017-09-08 |
| IL260750B2 (en) | 2024-02-01 |
| US11618789B2 (en) | 2023-04-04 |
| CN108699161B (zh) | 2022-06-03 |
| AU2017226960A1 (en) | 2018-08-09 |
| EP3423498A1 (en) | 2019-01-09 |
| US20230203189A1 (en) | 2023-06-29 |
| US20190077875A1 (en) | 2019-03-14 |
| IL305540B1 (en) | 2024-05-01 |
| IL305540B2 (en) | 2024-09-01 |
| JP7331168B2 (ja) | 2023-08-22 |
| AU2017226960B2 (en) | 2024-03-21 |
| US20240392034A1 (en) | 2024-11-28 |
| JP2019513346A (ja) | 2019-05-30 |
| IL305540A (en) | 2023-10-01 |
| JP2024169455A (ja) | 2024-12-05 |
| AU2024201503A1 (en) | 2024-03-28 |
| JP7557023B2 (ja) | 2024-09-26 |
| JP7362250B2 (ja) | 2023-10-17 |
| JP2022058881A (ja) | 2022-04-12 |
| KR102427948B1 (ko) | 2022-08-02 |
| JP7835815B2 (ja) | 2026-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201908813QA (en) | Anti-sirp alpha antibodies | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900269XA (en) | Channel sensing for independent links | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201805001UA (en) | Method of treating influenza a |